High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.
Antimicrob Agents Chemother
; 58(9): 5585-8, 2014 Sep.
Article
em En
| MEDLINE
| ID: mdl-24982070
ABSTRACT
We evaluated the activity of the novel spiropyrimidinetrione AZD0914 (DNA gyrase inhibitor) against clinical gonococcal isolates and international reference strains (n=250), including strains with diverse multidrug resistance and extensive drug resistance. The AZD0914 MICs were substantially lower than those of most other currently or previously recommended antimicrobials. AZD0914 should be further evaluated, including in vitro selection, in vivo emergence and mechanisms of resistance, pharmacokinetics/pharmacodynamics in humans, optimal dosing, and performance, in appropriate randomized and controlled clinical trials.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Compostos de Espiro
/
Barbitúricos
/
Gonorreia
/
DNA Girase
/
Inibidores da Topoisomerase II
/
Neisseria gonorrhoeae
Tipo de estudo:
Clinical_trials
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article